Based on promising initial phase I data of dinutuximab alone and in combination with granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) to enhance ADCC (99–101), the COG conducted the randomized phase 3 study ANBL0032 to evaluate the addition of dinutuximab with GM-CSF and IL-2 to standard isotretinoin post-consolidation therapy for high-risk neuroblastoma patients. Here, IL2 is linked to neuroblastoma.